PRKAA1 and leukemia: In this regard, Monlish et al [11] demonstrated that AMPK is not necessary for T-cell–dependent anti-leukemic activity, as transplantation of AMPK-dKO T cells in an allogeneic leukemia model reduced tumor burden to a similar degree and promoted equivalent survival of B62DF1 recipients at 4 and 10 weeks post-transplant.